Form 4: SI-BONE Director Sells 20,000 Shares via 10b5-1 Plan

SI-BONE, Inc. Director Jeffrey W. Dunn reported the future sale of 20,000 common shares at a weighted-average price of $21.2753, executed under a 10b5-1 trading plan.

Summary

• Jeffrey W. Dunn, a Director of SI-BONE, Inc. (SIBN), reported a planned sale of 20,000 shares of common stock.
• The transaction is scheduled for January 8, 2026.
• The shares were sold at a weighted-average price of $21.2753, with individual transactions ranging from $20.84 to $21.84.
• This sale was conducted pursuant to a Rule 10b5-1 trading plan established on May 7, 2025.
• Following this transaction, Mr. Dunn will beneficially own 80,115 shares indirectly through a trust and 10,307 shares directly, representing restricted stock units.

Sentiment

Score: 4

Explanation: The sale of 20,000 shares by a director is a negative signal, but the execution under a pre-arranged 10b5-1 plan reduces the immediate concern that the sale is based on new, undisclosed negative information.

Positives

• The sale was executed under a pre-arranged 10b5-1 trading plan, indicating a planned transaction rather than an immediate reaction to new, undisclosed information.

Negatives

• A director selling 20,000 shares could be perceived negatively by the market, as insider selling might suggest a lack of confidence or a desire to diversify.

Risks

• Potential negative market perception due to insider selling, which could put downward pressure on the stock price.

Future Outlook

This filing reports a future insider transaction scheduled for January 8, 2026, under a pre-established 10b5-1 plan. It does not provide any forward-looking statements or guidance regarding the company's operational or financial performance.

Management Comments

• No direct management comments or quotes were provided in this Form 4 filing.

Industry Context

This Form 4 filing details an individual director's stock transaction and does not provide information directly related to broader industry trends or competitive landscape within the medical device sector.

Stakeholder Impact

• Shareholders: May perceive insider selling negatively, potentially leading to downward pressure on the stock price.

Next Steps

• The transaction is scheduled to occur on January 8, 2026.

Key Dates

Recommendation

While insider selling can be a negative signal, this transaction is pre-planned under a 10b5-1 plan, which suggests it's for personal financial management rather than a reaction to new, adverse company developments. Without additional financial or operational news, this single event is not sufficient to change a fundamental investment thesis, thus a 'hold' stance is appropriate to observe further developments.

Keywords

SI-BONE, SIBN, Jeffrey W. Dunn, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Director, Medical Devices